81 related articles for article (PubMed ID: 14648016)
1. Interferon-gamma pharmacokinetics and pharmacodynamics in patients with colorectal cancer.
Turner PK; Houghton JA; Petak I; Tillman DM; Douglas L; Schwartzberg L; Billups CA; Panetta JC; Stewart CF
Cancer Chemother Pharmacol; 2004 Mar; 53(3):253-60. PubMed ID: 14648016
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the Fas signaling pathway by IFN-gamma in therapy of colon cancer: phase I trial and correlative studies of IFN-gamma, 5-fluorouracil, and leucovorin.
Schwartzberg LS; Petak I; Stewart C; Turner PK; Ashley J; Tillman DM; Douglas L; Tan M; Billups C; Mihalik R; Weir A; Tauer K; Shope S; Houghton JA
Clin Cancer Res; 2002 Aug; 8(8):2488-98. PubMed ID: 12171874
[TBL] [Abstract][Full Text] [Related]
3. Interferon-gamma-induced sensitization of colon carcinomas to ZD9331 targets caspases, downstream of Fas, independent of mitochondrial signaling and the inhibitor of apoptosis survivin.
Geller J; Petak I; Szucs KS; Nagy K; Tillman DM; Houghton JA
Clin Cancer Res; 2003 Dec; 9(17):6504-15. PubMed ID: 14695155
[TBL] [Abstract][Full Text] [Related]
4. A Fas-dependent component in 5-fluorouracil/leucovorin-induced cytotoxicity in colon carcinoma cells.
Tillman DM; Petak I; Houghton JA
Clin Cancer Res; 1999 Feb; 5(2):425-30. PubMed ID: 10037193
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
[TBL] [Abstract][Full Text] [Related]
6. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: evaluation of long-term target C(2).
Brunet M; Campistol JM; Millán O; Vidal E; Esforzado N; Rojo I; Jiménez O; Oppenheimer F; Corbella J; Martorell J
Int Immunopharmacol; 2003 Jul; 3(7):987-99. PubMed ID: 12810356
[TBL] [Abstract][Full Text] [Related]
8. Interferon-alpha and interferon-gamma sensitize human tenon fibroblasts to mitomycin-C.
Wang XY; Crowston JG; Zoellner H; Healey PR
Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3655-61. PubMed ID: 17652735
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
[TBL] [Abstract][Full Text] [Related]
10. 5-fluorouracil pharmacokinetics predicts disease-free survival in patients administered adjuvant chemotherapy for colorectal cancer.
Di Paolo A; Lencioni M; Amatori F; Di Donato S; Bocci G; Orlandini C; Lastella M; Federici F; Iannopollo M; Falcone A; Ricci S; Del Tacca M; Danesi R
Clin Cancer Res; 2008 May; 14(9):2749-55. PubMed ID: 18451241
[TBL] [Abstract][Full Text] [Related]
11. The effectors of killer activity induced by interferon-alpha and gamma in peripheral blood mononuclear cells.
Sakaguchi M; Kubota S; Nishikido M; Taniguchi K; Inuzuka S; Saito Y; Kanetake H; Koga S
Int J Mol Med; 2002 Sep; 10(3):317-20. PubMed ID: 12165807
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of the oral fluoropyrimidine S-1 on a once-daily-for-28-day schedule in patients with advanced malignancies.
Chu QS; Hammond LA; Schwartz G; Ochoa L; Rha SY; Denis L; Molpus K; Roedig B; Letrent SP; Damle B; DeCillis AP; Rowinsky EK
Clin Cancer Res; 2004 Aug; 10(15):4913-21. PubMed ID: 15297391
[TBL] [Abstract][Full Text] [Related]
13. Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family.
Masci P; Olencki T; Wood L; Rybicki L; Jacobs B; Williams B; Faber P; Bukowski R; Tong K; Borden EC
Clin Pharmacol Ther; 2007 Mar; 81(3):354-61. PubMed ID: 17339865
[TBL] [Abstract][Full Text] [Related]
14. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
15. Interferon-gamma sensitizes osteosarcoma cells to Fas-induced apoptosis by up-regulating Fas receptors and caspase-8.
Inaba H; Glibetic M; Buck S; Ravindranath Y; Kaplan J
Pediatr Blood Cancer; 2004 Dec; 43(7):729-36. PubMed ID: 15390286
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic study of IST-622, a novel synthetic derivative of chartreusin, by oral administration in a phase II study of patients with breast cancer.
Asai G; Yamamoto N; Toi M; Shin E; Nishiyama K; Sekine T; Nomura Y; Takashima S; Kimura M; Tominaga T
Cancer Chemother Pharmacol; 2002 Jun; 49(6):468-72. PubMed ID: 12107551
[TBL] [Abstract][Full Text] [Related]
17. Mycophenolic acid inhibits SLE-associated cytokine expression and promotes apoptosis of peripheral blood mononuclear cells from patients with systemic lupus erythematosus.
Su DL; Wang HJ; Ji XH; Li YY; Xuan HB; Heng C; Li YF
Acta Pharmacol Sin; 2006 Aug; 27(8):1051-7. PubMed ID: 16867258
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancer.
Kho Y; Jansman FG; Prins NH; Neef C; Brouwers JR
Ther Drug Monit; 2006 Apr; 28(2):206-11. PubMed ID: 16628132
[TBL] [Abstract][Full Text] [Related]
19. FAS/FAS ligand ratio: a marker of oxaliplatin-based intrinsic and acquired resistance in advanced colorectal cancer.
Nadal C; Maurel J; Gallego R; Castells A; Longarón R; Marmol M; Sanz S; Molina R; Martin-Richard M; Gascón P
Clin Cancer Res; 2005 Jul; 11(13):4770-4. PubMed ID: 16000573
[TBL] [Abstract][Full Text] [Related]
20. Role of the Fas/FasL pathway in combination therapy with interferon-alpha and fluorouracil against hepatocellular carcinoma in vitro.
Nakamura M; Nagano H; Sakon M; Yamamoto T; Ota H; Wada H; Damdinsuren B; Noda T; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Nakamori S; Dono K; Monden M
J Hepatol; 2007 Jan; 46(1):77-88. PubMed ID: 17045692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
